Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
about
Practices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic studySecond-line systemic therapy for metastatic colorectal cancer.The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysisRNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trialsTreatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.The Globalization of Cooperative Groups.Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients.Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer.Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status.New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy.Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials.Fucosylation is a common glycosylation type in pancreatic cancer stem cell-like phenotypes.A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.2-Methoxy-5-amino-N-hydroxybenzamide, a derivative of mesalamine, inhibits colon cancer cell growth through cyclo-oxygenase-2-dependent and -independent mechanisms.Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.Non-response to preoperative chemotherapy is a contraindication to hepatectomy plus radiofrequency ablation in patients with colorectal liver metastases.Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases.Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.Prospective Quality of Life Study for Colorectal Cancer Patients with Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
P2860
Q24289045-F5D18E58-B40C-471B-BE29-035728EF8365Q30238760-8AFBBFE0-726A-4E2C-AB2E-CD85B3E90928Q30240061-43EAD09D-4CE4-45EC-9E91-00D3C99DA4CEQ34028959-965647CC-A5A0-4461-9FD1-2D43E9849ABCQ35082383-54F9A398-109A-4690-AF63-982A178FC706Q35234665-6375779A-8893-4452-B173-18C2084FEC07Q35375761-53772849-2E8D-4947-AD4B-25FDAD1226BBQ35721069-15D693A3-23DD-4126-A335-A63C5F483040Q36119749-4D981D3B-78BE-4943-939D-F4563037E15EQ36219570-AC22462B-F80F-4B22-A753-FBB94D67EB71Q36813649-76F65C9F-B99F-46EC-8ECF-5851ECC2680AQ37401956-B918377D-6B74-4B17-AD7B-11070DFEFDAEQ37975508-B16CDF6B-45EA-4E40-A1E3-ADAC044D0C6BQ38112587-7FFD468B-523E-4892-9F1E-D3FB5CA6811DQ38228850-9A62EDB9-4959-4897-9F34-0D14DE9E9E4DQ38889830-6A68D55F-FC62-4728-B2F8-8B628C711D9FQ39139284-58C6E3F8-1A58-4E13-AF30-60D181BC7BE2Q39376007-A815BCA7-5F8F-4542-B496-24BBFCFFE99BQ40674654-DBDE1949-0AA9-414B-8246-3A922B63E871Q43009882-80CFB3FA-32B3-4CF6-BCB0-FF37E4723590Q44794355-FB4E0533-4386-4D1A-939D-ABD55A1DF5F0Q46735002-D0EEE7C4-1F2F-42E9-83FC-77802381AB2EQ47789478-92613CF0-4590-41DC-B724-D4939A5564AA
P2860
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase III noninferiority trial ...... ated with fluorouracil: N9841.
@ast
Phase III noninferiority trial ...... ated with fluorouracil: N9841.
@en
Phase III noninferiority trial ...... ated with fluorouracil: N9841.
@nl
type
label
Phase III noninferiority trial ...... ated with fluorouracil: N9841.
@ast
Phase III noninferiority trial ...... ated with fluorouracil: N9841.
@en
Phase III noninferiority trial ...... ated with fluorouracil: N9841.
@nl
prefLabel
Phase III noninferiority trial ...... ated with fluorouracil: N9841.
@ast
Phase III noninferiority trial ...... ated with fluorouracil: N9841.
@en
Phase III noninferiority trial ...... ated with fluorouracil: N9841.
@nl
P2093
P2860
P356
P1476
Phase III noninferiority trial ...... ated with fluorouracil: N9841.
@en
P2093
Abraham P Mathews
Daniel J Sargent
Edith Mitchell
George P Kim
Henry C Pitot
Kendrith M Rowland
Michelle R Mahoney
Philip A Philip
Richard M Goldberg
Steven R Alberts
P2860
P304
P356
10.1200/JCO.2008.20.4552
P407
P577
2009-04-20T00:00:00Z